logo-loader
RNS
Diaceutics PLC

Diaceutics PLC - Issue of Share Options / PDMR Shareholdings

RNS Number : 8615G
Diaceutics PLC
01 April 2022
 

1 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 871,411 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan.

 

Share Options were granted as follows:

 

Name

Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Effective Grant date

Peter Keeling, CEO

79,303

332,845

0.40%

1 April 2022

Nick Roberts, CFO

41,838

41,838

0.05%

1 April 2022

Ryan Keeling, CIO

72,290

316,444

0.38%

1 April 2022

Julie Browne, COO and PDMR

51,938

51,938

0.06%

1 April 2022

Jordan Clark, CCO and PDMR

50,495

50,495

0.06%

1 April 2022

Susanne Munksted, CPO and PDMR

50,953

174,075

0.21%

1 April 2022

Stefan McDonald, CGO and PDMR

48,463

81,722

0.10%

1 April 2022

Other employees (34 persons)

476,131

1,095,823

1.30%

    1 April 2022

 

 

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, including any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 31 March 2021. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

 

Following this grant, the total number of share options outstanding in the Company is 3,191,161, representing approximately 3.80% of its current issued share capital of 84,063,923.

 

Enquiries:

Diaceutics PLC 

 

Peter Keeling, Chief Executive Officer

Via Alma PR 

Nick Roberts, Chief Financial Officer

 

 

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison, Stewart Wallace, Nick Adams

 

 

 

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde, Kieran Breheny, Matthew Young

diaceutics@almapr.co.uk


About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Peter Keeling

2

Reason for notification

  

a.

Position/Status

CEO, Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

79,303

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Nick Roberts

2

Reason for notification

  

a.

Position/Status

CFO, Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

41,838

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Ryan Keeling

2

Reason for notification

  

a.

Position/Status

CIO, Director

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

72,290

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Julie Browne

2

Reason for notification

  

a.

Position/Status

COO and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

51,938

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification

  

a.

Position/Status

CCO and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

50,495

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

  

a.

Position/Status

CPO and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

50,953

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Stefan McDonald

2

Reason for notification

  

a.

Position/Status

CGO and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over new ordinary shares of 0.2p each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Grant of share options

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

Exercise price of 0.2p per share

48,463

 

 

e.

Date of the transaction

1 April 2022

f.

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGZGFFLMRGZZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

7 min read